🔬 Understanding the Science behind new Drugs... the Essential Role of PK/PD Studies 💊 Pharmacokinetic/pharmacodynamic (PK/PD) studies are more than just technical analyses. They are at the heart of pharmaceutical research, helping us decode how a drug interacts with the body and how it exerts its effects. From absorption to therapeutic action, each step is crucial to ensuring both efficacy and safety. Discover how Oncodesign Services can support you for PK/PD studies: https://buff.ly/3yQlyJU #Pharmacology #PreClinicalResearch #PKPD #Innovation #Health
Oncodesign Services
Recherche en biotechnologie
CRO spécialisée en drug discovery et services précliniques
À propos
Oncodesign Services est société de recherche contractuelle (CRO) spécialisée dans la découverte de médicaments et les services précliniques. Fondée en 1995, Oncodesign Services a pour mission de contribuer à la découverte de thérapies innovantes, dans les domaines de l'oncologie, de l'inflammation et des maladies infectieuses. De l'identification de cible jusqu'au dépôt d'IND, Oncodesign Services accompagne les programmes R&D de clients internationaux (laboratoires pharmaceutiques, biotechs, instituts de recherche). Oncodesign Services propose une gamme complète de services de drug discovery tels que la chimie médicinale, la DMPK, la pharmaco-imagerie, la bioanalyse, les tests in vivo/in vitro et les modèles de tumeurs. Nos capacités couvrent les petites molécules, les théranostiques et les nouvelles entités biologiques, soit par des projets autonomes (SOLO), ou par des programmes intégrés (DRIVE). Pionnier en médecine translationnelle, le défi de l'entreprise repose sur une accélération des cadences pour un développement plus rapide – du laboratoire au patient – mais aussi sur l’élaboration d’une proposition thérapeutique différenciée et innovante. Pour cela, Oncodesign Services utilise de nouvelles voies technologiques pour identifier et sélectionner les meilleurs candidats médicaments. Oncodesign Services dispose de laboratoires BSL1, BSL2 et BSL3 et tous les sites maintiennent l'accréditation internationale AAALAC de notre programme de soin et d'utilisation des animaux. Basé à Dijon, au sein du pôle Paris-Saclay et à Montréal, Oncodesign Services bénéficie de 2000m² de laboratoires de chimie et biologie à la pointe de la technologie. Oncodesign Services compte 230 collaborateurs en France, au Canada et aux Etats-Unis, avec de hautes compétences en drug discovery et pharmacologie translationnelle.
- Seite web
-
https://www.oncodesign-services.com
Lien externe pour Oncodesign Services
- Secteur
- Recherche en biotechnologie
- Größe des Unternehmens
- 201-500 employés
- Siège social
- Dijon Cedex
- Typ
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 1995
- Domains
- Kinase inhibitor Drug & Biomarker Discovery, Novel inflammatory target based drug discovery, Oncology advanced in vitro and in vivo pharmacology, Immunomodulation in oncology, DMPK/ADME, Medicinal chemistry, Bioanalysis, Translational Biomarkers, Biobanking, Biodecontamination/Biosafety, medicinal chemistry, drug discovery, drug analysis, Biopharma, Partnering, inflammatory diseases, infectious diseases, vitro assay development et vivo models
Lieux
-
Direktorin
20, rue Jean Mazen
BP 27627
21076 Dijon Cedex, FR
-
25-27 avenue du Quebec
91140 Villebon-sur-Yvette, Ile-de-France, FR
-
400 Technology Square
Lower level
02139 Cambridge, MA, US
-
11-2901 Rue Rachel Est
QC H1W 4A4 Montréal, CANADA, CA
Employés chez Oncodesign Services
Nouvelles
-
[CONGRESS] Heading north 🧭 direction Sweden for the Nordic Life Science (NLS) Days Feel free to discuss with Oncodesign Services and discover how our technology platform could support your programs from Hit Identification to IND. We look forward to seeing you there ! 📆 18th to 19th September 📍 Malmö, Sweden #PreclinicalServices #DrugDiscovery #CRO #NLSDays
-
💊 A new in vivo model for Melanoma 🔬 Get access to a novel ectopic/orthotopic model that recapitulates genetic drivers found in a significant proportion of human melanoma: ▶️ YUMM1.7 ◀️ This syngeneic model is now available for evaluating your new therapies. Learn more information here: https://buff.ly/3WZqGoq #melanoma #oncology #research #model #preclinical "immunooncology
-
[Focus on… Infectious diseases] Following the COVID19 epidemia, we swiftly deploy a comprehensive panel of preclinical solutions. Today, we have expanded our capabilities with a number of pathogens. 🔬 Oncodesign Services offers preclinical solutions in infectious diseases including Dengue and MonkeyPox. Learn more here : https://buff.ly/3MijrSe #preclinicalmodels #CROservices #infectious
ABSL2 | ABSL3 | Infectious Disease | Oncodesign Services
oncodesign-services.com
-
Rats have been used to mimic human disease and pathology for more than a century. 🐀 Their size and physiological similarity to humans make them ideal for a wide range of scientific fields, including toxicology. Discover in this infographic their advantages in preclinical oncology 👇 #ratmodels #preclinicalservices #oncology #CRO
-
📸 Notizie da Roma ! 📸 We're excited to welcome you at booth #15 with some blackcurrent sweet, delightful treats from Dijon! Come chat with us about your drug discovery projects! #EFMC2024
-
[POSTER] Our latest study, in collaboration with Taconic delves into the pivotal role of Humanized Immune System (HIS) mice in immuno-oncology research. In this poster, we explore how knocking out murine Fc gamma receptors (FcγRs) in a super- immunodeficient mouse model impacts the efficacy of anti-PD1 therapy, using pembrolizumab as our focus. Read the poster 👇 https://buff.ly/3YwmjSH #Oncology #VivoModels #PreclinicalServices
-
[CONGRESS] Back on the road, direction Rome ✈️ for the 28th EFMC-ISMC Symposium on #MedChem. Come and chat with Oncodesign Services and ZoBio , booth #15. We will be thrilled to present our technology platform to support your programs from Hit Identification to IND. 📆 1st to 5th September 2024 📍 Rome, Italy #SmallMolecule #DrugDiscovery #CRO #EFMC
-
[BLOG] Oncolytic viruses (OVs) are used to destroy cancer cells and leverage the host immune system to enhance the effect. Learn more in this blog about their mechanism used to stimulate an immune response. 👉 https://buff.ly/4d0PTEt
-
🤔 How using #PDX #Models for translational research demonstrate ways to overcome resistance? Based on the scientific paper "𝐃𝐨𝐮𝐛𝐥𝐞𝐭 𝐚𝐧𝐝 𝐓𝐫𝐢𝐩𝐥𝐞𝐭 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐄𝐫𝐢𝐛𝐮𝐥𝐢𝐧, 𝐅𝐮𝐥𝐯𝐞𝐬𝐭𝐫𝐚𝐧𝐭, 𝐚𝐧𝐝 𝐏𝐚𝐥𝐛𝐨𝐜𝐢𝐜𝐥𝐢𝐛 𝐢𝐧 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐨𝐝𝐞𝐥𝐬" published earlier in the year and co-written by Oncodesign Services and Eisai Co., Ltd. , discover in this article a brief summary of the key findings to take away! Read now 👉https://buff.ly/3yC7vYd
Ähnliche Seiten
Parcourir les offres d'emploi
Financement
Dernier round
Dette après introduction en Bourse6 304 653,00 $US